1. Advances in Multiple Myeloma

2. This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States, and data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

3. Newly Diagnosed Multiple Myeloma

4. Advances in MM

5. Car/Len/Dex +/- ASCT or Car/Cyclo/Dex + ASCT in NDMM: The Forte Study

6. FORTE Results: MRD With Car/Len/Dex or Cyclophosphamide/Car/Dex in NDMM

7. ALCYONE Study: Dara/VMP vs VMP in ND Elderly Patients Ineligible for ASCT: Subgroup Analysis

8. Key Takeaways

9. Key Takeaways (cont)

10. Relapsed and Refractory Multiple Myeloma

11. Background

12. ARROW Study Once- vs Twice-Weekly Kd in RRMM

13. OPTIMISMM Study PVd vs Vd in RRMM With Prior Lenalidomide Exposure

14. MMY1001 Study D-Kd in Lenalidomide-Refractory, Relapsed MM

15. PAVO Study Subcutaneous Daratumumab in RRMM

16. ELOQUENT-3 Study EPd vs Pd for RRMM

17. Key Takeaways

18. Emerging Agents in Multiple Myeloma

19. Rationale for Emerging Agents in MM

20. CAR T Cell Therapy bb2121 in RRMM

21. Venetoclax in RRMM with t(11;14)

22. Venetoclax/Carfilzomib/Dex in RRMM

23. Isatuximab in MM

24. Selinexor Combinations

25. Selinexor + Dex in Penta-Refractory MM STORM Study

26. Pembrolizumab Current Status in MM

27. Key Takeaways

28. Clinical Practice Implications

29. Recent Data Implications for NDMM

30. Recent Data Implications for RRMM

31. Future Directions

32. Abbreviations

33. Abbreviations (cont)

34. Abbreviations (cont)

35. Abbreviations (cont)